{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:43:46Z","timestamp":1760060626131,"version":"build-2065373602"},"reference-count":21,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Transthyretin amyloidosis (ATTR) is a rare disease caused by misfolded proteins, amyloids, that are deposited in various organs and tissues, typically the heart and\/or nerves, causing the development of cardiomyopathy (CM) and polyneuropathy (PN). Although this may be an incurable disease, there are various treatments that are currently available for patients with ATTR, including transthyretin (TTR) silencers such as inotersen and patisiran. The silencers help slow down the progression of disease and improve the quality of life of patients with ATTR by alleviating the cardiac and neurological symptoms that patients present. The purpose of this study was to compare the cardiac findings observed in the 99Tc-PYP scintigraphy (PYP scan) parameters of patients with a mixed phenotype before and after treatment with inotersen or patisiran. This study included ten patients from the amyloidosis clinic at the University Health Network. All of the patients (average age: 63.80 \u00b1 11.70; 60.0% males, 40.0% females) received inotersen or patisiran as their treatment. These patients underwent a PYP scan before and after treatment to observe any improvements in terms of their CM post-treatment. Nine (90.0%) patients showed an improvement with their CM, as they showed a decrease in their heart-to-contralateral lung (H\/CL) ratio and\/or pyrophosphate (PYP) grade based on their results from the PYP scan post-treatment with a TTR silencer. Only one patient (10.0%) had worsening results, as their H\/CL ratio and PYP grade increased post-treatment in comparison to the PYP scan results pre-treatment. Patients with ATTR who have a mixed phenotype should undergo a PYP scan before and after treatment with a TTR silencer. By undergoing these scans, the effectiveness of this treatment could be determined by observing any improvements in the signs of CM. A decrease in the H\/CL ratio and\/or the PYP grade would indicate that the TTR silencer has been effective in alleviating the signs and symptoms of CM, and that the patients should continue with their treatment plan.<\/jats:p>","DOI":"10.3390\/jcdd12090342","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:51:21Z","timestamp":1757065881000},"page":"342","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Study on Cardiac Findings in Patients with Transthyretin Amyloidosis Before and After Treatment with a Transthyretin Silencer"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2169-3730","authenticated-orcid":false,"given":"Priya","family":"Arivalagan","sequence":"first","affiliation":[{"name":"Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, University of Toronto, 585 University Ave, PMB11-136, Toronto, ON M5G 2N2, Canada"},{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Hernan","family":"Delgado","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, University of Toronto, 585 University Ave, PMB11-136, Toronto, ON M5G 2N2, Canada"},{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sanguinetti, C., Minniti, M., Susini, V., Caponi, L., Panichella, G., Castiglione, V., Aimo, A., Emdin, M., Vergaro, G., and Franzini, M. (2022). The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081906"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17925\/HI.2023.17.1.27","article-title":"Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy","volume":"17","author":"Ioannou","year":"2023","journal-title":"Heart Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref_7","first-page":"19","article-title":"The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre","volume":"29","author":"Dower","year":"2022","journal-title":"Br. J. Cardiol."},{"key":"ref_8","first-page":"762","article-title":"A challenging road to diagnosing transthyretin cardiac amyloidosis and using technetium-99m pyrophosphate bone scintigraphy in nuclear cardiology\u2014A case report","volume":"76","author":"Kavita","year":"2021","journal-title":"Med. J. Malaysia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s12350-023-03203-9","article-title":"Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: The SCAN-MP study","volume":"30","author":"Pandey","year":"2023","journal-title":"J. Nucl. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11886-020-01374-2","article-title":"Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid","volume":"22","author":"Hough","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1055\/a-0848-9610","article-title":"Neue Therapieoptionen f\u00fcr die heredit\u00e4re Transthyretin-Amyloidose [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)]","volume":"144","author":"Zibert","year":"2019","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gales, L. (2019). Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020078"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A Review of Patisiran (ONPATTRO\u00ae) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40001-023-01629-y","article-title":"Optimizing cardiac amyloidosis assessment: Utility of 1-h and 3-h 99mTc-PYP imaging","volume":"29","author":"Imakhanova","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11604-022-01364-0","article-title":"New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy","volume":"41","author":"Matsuda","year":"2023","journal-title":"Jpn. J. Radiol."},{"key":"ref_16","unstructured":"Omerovic, S., and Jain, A. (2025). Echocardiogram. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_17","unstructured":"Kosaraju, A., Goyal, A., and Grigorova, Y. (2024, February 04). Left Ventricular Ejection Fraction. [Updated 2023 Apr 24], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459131\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"X1","DOI":"10.1530\/ERP-19-0050e","article-title":"Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: A guideline from the British Society of Echocardiography","volume":"7","author":"Harkness","year":"2020","journal-title":"Echo Res Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13598","DOI":"10.1111\/eci.13598","article-title":"Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients with Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40120-021-00268-x","article-title":"Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR","volume":"10","author":"Yarlas","year":"2021","journal-title":"Neurol. Ther."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/9\/342\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:56Z","timestamp":1760035196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/9\/342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcdd12090342"],"URL":"https:\/\/doi.org\/10.3390\/jcdd12090342","relation":{},"ISSN":["2308-3425"],"issn-type":[{"type":"electronic","value":"2308-3425"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}